These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 1329942

  • 1. [Immunohistochemical evidence of vimentin in fibrocystic breast disease and mammary carcinoma].
    Alexiev B, Valkov I, Popov A.
    Zentralbl Pathol; 1992 Sep; 138(4):284-8. PubMed ID: 1329942
    [Abstract] [Full Text] [Related]

  • 2. Coexpression patterns of vimentin and glial filament protein with cytokeratins in the normal, hyperplastic, and neoplastic breast.
    Gould VE, Koukoulis GK, Jansson DS, Nagle RB, Franke WW, Moll R.
    Am J Pathol; 1990 Nov; 137(5):1143-55. PubMed ID: 1700618
    [Abstract] [Full Text] [Related]

  • 3. Analysis of the immunohistochemical expression of mammaglobin A in primary breast carcinoma and lymph node metastasis.
    Raica M, Cîmpean AM, Meche A, Alexa A, Suciu C, Mureşan A.
    Rom J Morphol Embryol; 2009 Nov; 50(3):341-7. PubMed ID: 19690758
    [Abstract] [Full Text] [Related]

  • 4. A comparison of the patterns of laminin expression in fibroadenoma, fibrocystic diseases, pre-invasive and invasive ductal breast carcinoma.
    Zheng WQ, Looi LM, Cheah PL.
    Pathology; 2001 Aug; 33(3):303-6. PubMed ID: 11523929
    [Abstract] [Full Text] [Related]

  • 5. New aspects of the natural history of in situ and invasive carcinoma in the female breast. Results from autopsy investigations.
    Andersen J, Nielsen M, Christensen L.
    Verh Dtsch Ges Pathol; 1985 Aug; 69():88-95. PubMed ID: 3006395
    [No Abstract] [Full Text] [Related]

  • 6. Vimentin is preferentially expressed in high-grade ductal and medullary, but not in lobular breast carcinomas.
    Domagala W, Woźniak L, Lasota J, Weber K, Osborn M.
    Am J Pathol; 1990 Nov; 137(5):1059-64. PubMed ID: 2173410
    [Abstract] [Full Text] [Related]

  • 7. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast.
    Brown LF, Guidi AJ, Schnitt SJ, Van De Water L, Iruela-Arispe ML, Yeo TK, Tognazzi K, Dvorak HF.
    Clin Cancer Res; 1999 May; 5(5):1041-56. PubMed ID: 10353737
    [Abstract] [Full Text] [Related]

  • 8. The pathologic profile of invasive breast cancer-ii) changes in the harboring mammary tissue and regional lymphnodes.
    Mehtani VG, Joshi K, Mehrotra GC.
    Indian J Pathol Microbiol; 1987 Oct; 30(4):415-22. PubMed ID: 2853136
    [No Abstract] [Full Text] [Related]

  • 9. [Diagnostic immunohistochemistry of breast epithelial lesions].
    Balaton AJ, Guinebretière JM, Penault-Llorca F.
    Ann Pathol; 2003 Dec; 23(6):570-81. PubMed ID: 15094595
    [Abstract] [Full Text] [Related]

  • 10. Laminin production and fibronectin immunoreactivity in breast carcinomas.
    Gorczyca W, Holm R, Nesland JM.
    Anticancer Res; 1993 Dec; 13(4):851-8. PubMed ID: 8394677
    [Abstract] [Full Text] [Related]

  • 11. [Immunocytochemical demonstration of actin in myothelial cells in proliferative diseases of the breast].
    Walther B, Rutter G, Stegner HE, Böcker W.
    Pathologe; 1986 Nov; 7(6):318-23. PubMed ID: 3027685
    [No Abstract] [Full Text] [Related]

  • 12. [Breast cancer].
    Van Bogaert LJ.
    Rev Fr Gynecol Obstet; 1984 May; 79(5):361-98. PubMed ID: 6098952
    [No Abstract] [Full Text] [Related]

  • 13. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
    Khalifeh IM, Albarracin C, Diaz LK, Symmans FW, Edgerton ME, Hwang RF, Sneige N.
    Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
    [Abstract] [Full Text] [Related]

  • 14. Cathepsin D in invasive ductal NOS breast carcinoma as defined by immunohistochemistry. No correlation with survival at 5 years.
    Domagala W, Striker G, Szadowska A, Dukowicz A, Weber K, Osborn M.
    Am J Pathol; 1992 Nov; 141(5):1003-12. PubMed ID: 1332483
    [Abstract] [Full Text] [Related]

  • 15. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
    Latta EK, Tjan S, Parkes RK, O'Malley FP.
    Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
    [Abstract] [Full Text] [Related]

  • 16. [Morphology, topography and growth pattern of benign proliferative breast lesions and pre-invasive cancers].
    Böcker W, Jarasch ED, Nagle EB, Höhne R.
    Verh Dtsch Ges Pathol; 1985 Dec; 69():96-107. PubMed ID: 3006396
    [No Abstract] [Full Text] [Related]

  • 17. Alpha-methylacyl-CoA racemase protein expression is associated with the degree of differentiation in breast cancer using quantitative image analysis.
    Witkiewicz AK, Varambally S, Shen R, Mehra R, Sabel MS, Ghosh D, Chinnaiyan AM, Rubin MA, Kleer CG.
    Cancer Epidemiol Biomarkers Prev; 2005 Jun; 14(6):1418-23. PubMed ID: 15941950
    [Abstract] [Full Text] [Related]

  • 18. The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study.
    Salvucci O, Bouchard A, Baccarelli A, Deschênes J, Sauter G, Simon R, Bianchi R, Basik M.
    Breast Cancer Res Treat; 2006 Jun; 97(3):275-83. PubMed ID: 16344916
    [Abstract] [Full Text] [Related]

  • 19. The significance of intraduct appearances in breast cancer.
    Cowen PN, Bates C.
    Clin Oncol; 1984 Mar; 10(1):67-72. PubMed ID: 6323084
    [Abstract] [Full Text] [Related]

  • 20. Definition of precancerous and high-risk mammary lesions.
    Bégin LR.
    Can J Surg; 1985 May; 28(3):248-51. PubMed ID: 2986807
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.